Business Wire

Advent Technologies signs Supply Agreement with the German State of Brandenburg for Fuel Cell Systems

Share

Advent Technologies Holdings, Inc. (NASDAQ: ADN) ("Advent" or the "Company"), an innovation-driven leader in the fuel cell and hydrogen technology sectors, is pleased to announce the signing of a three-year agreement with the German State of Brandenburg for the supply of methanol-powered fuel cell systems, which will be installed in select critical communication sites in the region.

Advent's methanol-powered fuel cell systems will be used as a back-up power source for Brandenburg's BOS digital radio network, replacing the diesel-driven emergency power systems at several sites over the next three years. Germany's old public safety and security infrastructure relied on an outdated analogue radio system for communication. BOS is a digital, encrypted, and secure means of communication. The new BOS network allows first responders and other public safety officials to communicate easily and securely. The BOS network now covers 99.2% of German territory.

Advent's solution was selected as part of a tender launched by the German State of Brandenburg, which requested that fuel cell and hydrogen technology companies submit proposals for sustainable and reliable emergency power supply solutions. Prior to Advent's selection, the performance of the Company's methanol-powered fuel cells was tested at a site of the BOS digital radio network in Brandenburg, providing further proof of concept for the use of HT-PEM fuel cells as an efficient back-up power source for critical infrastructure applications. Advent's methanol-powered fuel cells deliver reliable power in an environmentally friendly way – reducing CO2 emissions and operating silently – while having a low impact on the surroundings. Methanol, as a carrier of hydrogen, allows simpler storage than pure hydrogen and enhances the safety of operations.

"We are thrilled that the German State of Brandenburg endorses Advent’s products for Brandenburg’s critical communication needs and are confident that Advent’s methanol-powered fuel cell systems will ensure the seamless operation of the entire BOS digital radio network in the region. This new partnership marks a major step towards the wider adoption of HT-PEM fuel cells as a back-up power source in critical infrastructure applications across Europe. We look forward to joining similar projects in the near future,” stated Advent Technologies GmbH Senior Vice President, Daniel Hennig.

"The Advent team is proud and excited to start this new collaboration with the German State of Brandenburg. Now, more than ever, the world needs zero-emission back-up power solutions to ensure a clean and uninterrupted energy supply. Today's agreement is another testament on how Advent’s methanol-powered fuel cells can play a major role in supporting critical infrastructure power requirements around the globe. We look forward to a long and successful collaboration with our new partner," added Dr. Vasilis Gregoriou, Advent Technologies Chief Executive Officer and Executive Chairman of the Board.

About Advent Technologies Holdings, Inc.

Advent Technologies Holdings, Inc. is a U.S. corporation that develops, manufactures, and assembles complete fuel cell systems as well as supplying customers with critical components for fuel cells in the renewable energy sector. Advent is headquartered in Boston, Massachusetts, with offices in California, Greece, Denmark, Germany, and the Philippines. With more than 150 patents issued, pending, and/or licensed for fuel cell technology, Advent holds the IP for next-generation HT-PEM that enables various fuels to function at high temperatures and under extreme conditions – offering a flexible fuel option for the automotive, aviation, defense, oil and gas, marine, and power generation sectors. For more information, visit www.advent.energy.

Cautionary Note Regarding Forward-Looking Statements

This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” and other words of similar meaning. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the Company’s ability to maintain the listing of the Company’s common stock on Nasdaq; future financial performance; public securities’ potential liquidity and trading; impact from the outcome of any known and unknown litigation; ability to forecast and maintain an adequate rate of revenue growth and appropriately plan its expenses; expectations regarding future expenditures; future mix of revenue and effect on gross margins; attraction and retention of qualified directors, officers, employees and key personnel; ability to compete effectively in a competitive industry; ability to protect and enhance Advent’s corporate reputation and brand; expectations concerning its relationships and actions with technology partners and other third parties; impact from future regulatory, judicial and legislative changes to the industry; ability to locate and acquire complementary technologies or services and integrate those into the Company’s business; future arrangements with, or investments in, other entities or associations; and intense competition and competitive pressure from other companies worldwide in the industries in which the Company will operate; and the risks identified under the heading “Risk Factors” in Advent’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 31, 2022, as well as the other information filed with the SEC. Investors are cautioned not to place considerable reliance on the forward-looking statements contained in this press release. You are encouraged to read Advent’s filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements. Advent’s business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Advent Technologies Holdings, Inc.
Elisabeth Maragoula/Michael Trontzos
press@advent.energy

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Forge Biologics Fuels Gene Therapy Manufacturing Engine with Launch of Plasmid DNA Manufacturing Services to Support AAV Clients27.9.2022 14:00:00 EEST | Press release

Forge Biologics, a gene therapy-focused contract development and manufacturing organization, today announced the new availability of plasmid DNA manufacturing to its suite of scalable manufacturing services for gene therapy programs, complementing Forge’s existing AAV process development, analytical development, cGMP manufacturing, and automated final fill capabilities. Forge’s plasmid manufacturing services encompass three grades to accommodate a phase-appropriate approach: Research-Grade, suitable for discovery, research and development; GMP-Pathway, suitable for early-stage clinical trial cGMP AAV manufacturing, and cGMP, suitable for late-stage clinical and commercial cGMP manufacturing. Forge’s plasmid production services utilize single-use systems that seamlessly integrate into the Company’s platform AAV manufacturing process, allowing continuity of manufacturing for clients and streamlined vendor management. Research-Grade and GMP-Pathway plasmid grades are currently available,

DOQMIND Announces Peter Hulsmans as CEO27.9.2022 14:00:00 EEST | Press release

DOQMIND (www.DOQMIND.com), a leading label and artwork management technology provider, announced today that Peter Hulsmans has been appointed CEO. With more than 20 years of label and artwork management leadership experience, Hulsmans brings a high-growth, customer-focused mindset to DOQMIND. “Peter’s experience and extensive industry knowledge make him the right person to build momentum and drive DOQMIND’s aggressive expansion plans,” said Ignace Cosaert, a board member of Athena Graphics, DOQMIND’s founding company. “Peter is known in the industry as someone who always delivers on his customer commitments, aligned with Athena’s reputation for delivering high-quality prepress services since 1991. He will be an excellent steward of our values, products, and brand portfolio.” DOQMIND has been providing label and artwork management technology to some of the most well-known brands for the last 15 years as part of Athena’s product portfolio. Its growth has positioned the company to spin of

Latest Blue Shift Report From Arthur D. Little Delivers Realistic View of the Metaverse27.9.2022 13:26:00 EEST | Press release

Arthur D. Little (ADL) has published The Metaverse, beyond fantasy, the latest in a series of new reports from the company running under the ‘Blue Shift’ banner, which explore the impact of new technologies on business, society and humans. The Metaverse, Beyond Fantasy looks beyond the hype and delivers a realistic picture of the Metaverse for businesses, focusing in particular on the technologies necessary to enable it. While the Metaverse is not a new concept, the past few years have seen a rapid acceleration of both development and adoption, driven by the convergence of three industries: gaming; collaboration and productivity tools; and social media and networks. Yet while the size of the Metaverse market is difficult to estimate, the report emphasizes that companies should not underestimate its potential importance to their business. The report looks at the key enabling technologies of the Metaverse, including artificial intelligence (AI), Internet of Things (IoT) and blockchain, a

Adversaries Continue Cyberattack Onslaught with Greater Precision and Innovative Attack Methods according to 1H2022 NETSCOUT DDoS Threat Intelligence Report27.9.2022 13:05:00 EEST | Press release

NETSCOUT SYSTEMS, INC. (NASDAQ: NTCT) today announced findings from its 1H2022 DDoS Threat Intelligence Report. The findings demonstrate how sophisticated cybercriminals have become at bypassing defenses with new DDoS attack vectors and successful methodologies. "By constantly innovating and adapting, attackers are designing new, more effective DDoS attack vectors or doubling down on existing effective methodologies," said Richard Hummel, threat intelligence lead, NETSCOUT. "In the first half of 2022, attackers conducted more pre-attack reconnaissance, exercised a new attack vector called TP240 PhoneHome, created a tsunami of TCP flooding attacks, and rapidly expanded high-powered botnets to plague network-connected resources. In addition, bad actors have openly embraced online aggression with high-profile DDoS attack campaigns related to geopolitical unrest, which have had global implications." Deployed in most of the world's ISPs, large data centers, and government and enterprise net

EVER Pharma Launches the User-friendly D-mine® Pump Generated Report “DATA-mine®” to Enhance the Therapy Management of Parkinson’s Patients on Apomorphine27.9.2022 12:30:00 EEST | Press release

After successfully launching the D-mine ® Pump, a micro infusion device designed to provide precise continuous subcutaneous drug delivery for PD patients, the product family has been extended to include a comprehensive data history readout. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220915005029/en/ The user-friendly DATA-mine® REPORT (Graphic: Business Wire) EVER Pharma, a specialist in neurology and specialty pharmaceuticals, offers a complete therapy package for PD patients with Dacepton® (Dopaceptin®, Apomorphine hydrochloride), D-mine® Pump, D-mine ® Pen and now the DATA-mine® REPORT, a tool to read out the data of the D-mine ® Pump. Through this tool the D-mine ® Pump history file can be easily transformed into a handy report in PDF format, on Windows or macOS devices allowing Healthcare Professionals to navigate through the various parameters of the infusion therapy like dosing, flow rates, and time settings in ea

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom